Effect of Food on the Pharmacokinetics of Anaplastic Lymphoma Kinase (Alk) Inhibitor Ceritinib 750mg in Healthy Subjects.

Trial Profile

Effect of Food on the Pharmacokinetics of Anaplastic Lymphoma Kinase (Alk) Inhibitor Ceritinib 750mg in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2016

At a glance

  • Drugs Ceritinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top